Nicotine receptor partial agonists for smoking cessation.

Journal article

BACKGROUND: Nicotine receptor partial agonists may help people to stop smoking by a combination of maintaining moderate levels of dopamine to counteract withdrawal symptoms (acting as an agonist) and reducing smoking satisfaction (acting as an antagonist). Varenicline was developed as a nicotine receptor partial agonist from cytisine, a drug widely used in central and eastern Europe for smoking cessation. The first trial reports of varenicline were released in 2006, and further trials have n...

Expand abstract

Authors: Cahill, K; Stead, L; Lancaster, T

• Publication status: Published
• Journal: Cochrane database of systematic reviews
• Issue: 2
• Pages: CD006103
• Publication date: 2011-01-01
• DOI: 10.1002/14651858.cd006103.pub5
• EISSN: 1469-493X
• ISSN: 1469-493X
• Language: English
• Keywords: Randomized Controlled Trials as Topic; Smoking Cessation; Nicotine; Quinolizines; Alkaloids; Nicotinic Agonists; Quinoxalines; Humans; Substance Withdrawal Syndrome; Bupropion; Benzazepines; Smoking; Azocines